Pericytes as targets in hereditary hemorrhagic telangiectasia

Frontiers in Genetics

Volumn 5, Issue FEB, 2015, Pages

  Thalgott, Jérémy ^a   Dos Santos Luis, Damien ^a   Lebrin, Franck ^a  

^a PSL RESEARCH UNIVERSITY   (France)

Author keywords

Angiogenesis; Pericyte; Rare vascular disease; Thalidomide; Transforming growth factor signaling

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; ENDOGLIN; GAP JUNCTION PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CAPILLARY BASEMENT MEMBRANE; CAPILLARY BLOOD; CELL ADHESION; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CONSTIPATION; DEEP VEIN THROMBOSIS; DOWN REGULATION; DROWSINESS; ENDOTHELIUM CELL; EPISTAXIS; HUMAN; LETHARGY; LIBIDO DISORDER; NONHUMAN; PERICYTE; PERIPHERAL NEUROPATHY; PHENOTYPE; PROTEIN PHOSPHORYLATION; RENDU OSLER WEBER DISEASE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84923608016     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2015.00037     Document Type: Review

References (165)

1. Abdalla, S. A., and Letarte, M. (2006). Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J. Med. Genet. 43, 97-110. doi: 10.1136/jmg.2005.030833
2. Alam, M. A., Sami, S., and Babu, S. (2011). Successful treatment of bleeding gastro intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide. BMJ Case Rep. 2011:bcr0820114585. doi: 10.1136/bcr.08.2011.4585
3. Allinson, K. R., Carvalho, R. L., van den Brink, S., Mummery, C. L., and Arthur, H. M. (2007). Generation of a floxed allele of the mouse endoglin gene. Genesis 45, 391-395. doi: 10.1002/dvg.20284
4. Armulik, A., Abramsson, A., and Betsholtz, C. (2005). Endothelial/pericyte interactions. Circ. Res. 97, 512-523. doi: 10.1161/01.RES.0000182903.16652.d7
5. Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., et al. (2010). Pericytes regulate the blood-brain barrier. Nature 468, 557-561. doi: 10.1038/nature09522
6. Armulik, A., Mäe, M., and Betsholtz, C. (2011). Pericytes and the blood-brain barrier: recent advances and implications for the delivery of CNS therapy. Ther. Deliv. 2, 419-422. doi: 10.4155/tde.11.23
7. Arnold, T. D., Niaudet, C., Pang, M. F., Siegenthaler, J., Gaengel, K., Jung, B., et al. (2014). Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking αVβ8-TGFβ signaling in the brain. Development 141, 4489-4499. doi: 10.1242/dev.107193
8. Arthur, H. M., Ure, J., Smith, A. J., Renforth, G., Wilson, D. I., Torsney, E., et al. (2000). Endoglin, an ancillary TGFb receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol. 217, 42-53. doi: 10.1006/dbio.1999.9534
9. Bader, B. L., Rayburn, H., Crowley, D., and Hynes, R. O. (1998). Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95, 507-519. doi: 10.1016/S0092-8674(00)81618-9
10. Bayrak-Toydemir, P., McDonald, J., Akarsu, N., Toydemir, R. M., Calderon, F., Tuncali, T., et al. (2006a). A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am. J. Med. Genet. A 140, 2155-2162. doi: 10.1002/ajmg.a.31450
11. Bayrak-Toydemir, P., McDonald, J., Markewitz, B., Lewin, S., Miller, F., Chou, L. S., et al. (2006b). Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am. J. Med. Genet. A 140, 463-470. doi: 10.1002/ajmg.a.31101
12. Beltramo, E., and Porta, M. (2013). Pericyte loss in diabetic retinopathy: mechanisms and consequences. Curr. Med. Chem. 20, 3218-3225. doi: 10.2174/09298673113209990022
13. Benedito, R., Rocha, S. F., Woeste, M., Zamykal, M., Radtke, F., Casanovas, O., et al. (2012). Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 484, 110-114. doi: 10.1038/nature10908
14. Blanco, F. J., Santibanez, J. F., Guerrero-Esteo, M., Langa, C., Vary, C. P., and Bernabeu, C. (2005). Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J. Cell. Physiol. 204, 574-584. doi: 10.1002/jcp.20311
15. Beppu, H., Ichinose, F., Kawai, N., Jones, R. C., Yu, P. B., Zapol, W. M., et al. (2004). BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L1241-L1247. doi: 10.1152/ajplung.00239.2004
16. Bossler, A. D., Richards, J., George, C., Godmilow, L., and Ganguly, A. (2006). Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum. Mutat. 27, 667-675. doi: 10.1002/humu.20342
17. Bourdeau, A., Dumont, D. J., and Letarte, M. (1999). A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 104, 1343-1351. doi: 10.1172/JCI8088
18. Bourdeau, A., Faughnan, M. E., and Letarte, M. (2000). Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc. Med. 10, 279-285. doi: 10.1016/S1050-1738(01)00062-7
19. Bourdeau, A., Faughnan, M. E., McDonald, M. L., Paterson, A. D., Wanless, I. R., and Letarte, M. (2001). Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am. J. Pathol. 158, 2011-2020. doi: 10.1016/S0002-9440(10)64673-1
20. Buscarini, E., Manfredi, G., Gazzaniga, P., Reduzzi, L., Danesino, C., Olivieri, C., et al. (2009). Thalidomide for treatment of chronic severe bleeding in hereditary hemorrhagic telangiectasia. Hemat. Meet. Rep. 2009, 3.
21. Cambier, S., Gline, S., Mu, D., Collins, R., Araya, J., Dolganov, G., et al. (2005). Integrin alpha(v)beta8-mediated activation of transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch. Am. J. Pathol. 166, 1883-1894. doi: 10.1016/S0002-9440(10)62497-2
22. Carmeliet, P., and Jain, R. K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307. doi: 10.1038/nature10144
23. Carmeliet, P., Mackman, N., Moons, L., Luther, T., Gressens, P., Van Vlaenderen, I., et al. (1996). Role of tissue factor in embryonic blood vessel development. Nature 383, 73-75. doi: 10.1038/383073a0
24. Carvalho, R. L., Itoh, F., Goumans, M. J., Lebrin, F., Kato, M., Takahashi, S., et al. (2007). Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice. J. Cell Sci. 120, 4269-4277. doi: 10.1242/jcs.013169
25. Carvalho, R. L., Jonker, L., Goumans, M. J., Larsson, J., Bouwman, P., Karlsson, S., et al. (2004). Defective paracrine signalling by TGFbeta in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development 131, 6237-6247. doi: 10.1242/dev.01529
26. Chang, H., Huylebroeck, D., Verschueren, K., Guo, Q., Matzuk, M. M., and Zwijsen, A. (1999). Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 126, 1631-1642.
27. Chen, H., Shi, S., Acosta, L., Li, W., Lu, J., Bao, S., et al. (2004). BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 131, 2219-2231. doi: 10.1242/dev.01094
28. Chen, W., Guo, Y., Walker, E. J., Shen, F., Jun, K., Oh, S. P., et al. (2013). Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain. Arterioscler. Thromb. Vasc. Biol. 3, 305-310. doi: 10.1161/ATVBAHA.112.300485
29. Choi, E. J., Kim, Y. H., Choe, S. W., Tak, Y. G., Garrido-Martin, E. M., Chang, M., et al. (2013). Enhanced responses to angiogenic cues underlie the pathogenesis of hereditary hemorrhagic telangiectasia 2. PLoS ONE 8:e63138. doi: 10.1371/journal.pone.0063138
30. Choi, E. J., Walker, E. J., Shen, F., Oh, S. P., Arthur, H. M., Young, W. L., et al. (2012). Minimal homozygous endothelial deletion of Eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse. Cerebrovasc. Dis. 33, 540-547. doi: 10.1159/000337762
31. Cirulli, A., Liso, A., D'Ovidio, F., Mestice, A., Pasculli, G., and Gallitelli, M. (2003). Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol. 110, 29-32. doi: 10.1159/000072411
32. Cole, S. G., Begbie, M. E., Wallace, G. M., and Shovlin, C. L. (2005). A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J. Med. Genet. 42, 577-582. doi: 10.1136/jmg.2004.028712
33. Covassin, L. D., Villefranc, J. A., Kacergis, M. C., Weinstein, B. M., and Lawson, N. D. (2006). Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc. Natl. Acad. Sci. U.S.A. 103, 6554-6559. doi: 10.1073/pnas.0506886103
34. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91, 4082-4085. doi: 10.1073/pnas.91.9.4082
35. Daneman, R., Zhou, L., Kebede, A. A., and Barres, B. A. (2010). Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468, 562-566. doi: 10.1038/nature09513
36. David, L., Mallet, C., Keramidas, M., Lamandé, N., Gasc, J. M., Dupuis-Girod, S., et al. (2008). Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 102, 914-922. doi: 10.1161/CIRCRESAHA.107.165530
37. David, L., Mallet, C., Mazerbourg, S., Feige, J. J., and Bailly, S. (2007). Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109, 1953-1961. doi: 10.1182/blood-2006-07-034124
38. de Gussem, E. M., Snijder, R. J., Disch, F. J., Zanen, P., Westermann, C. J., and Mager, J. J. (2009). The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 47, 85-88.
39. Díaz-Flores, L., Gutiérrez, R., Madrid, J. F., Varela, H., Valladares, F., Acosta, E., et al. (2009). Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 24, 909-969.
40. Dickson, M. C., Martin, J. S., Cousins, F. M., Kulkarni, A. B., Karlsson, S., and Akhurst, R. J. (1995). Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121, 1845-1854.
41. Dupuis-Girod, S., Ambrun, A., Decullier, E., Samson, G., Roux, A., Fargeton, A. E., et al. (2014). ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. MAbs 6, 794-799. doi: 10.4161/mabs.28025
42. Dupuis-Girod, S., Ginon, I., Saurin, J. C., Marion, D., Guillot, E., Decullier, E., et al. (2012). Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307, 948-955. doi: 10.1001/jama.2012.250
43. Eilken, H. M., and Adams, R. H. (2010). Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr. Opin. Cell Biol. 22, 617-625. doi: 10.1016/j.ceb.2010.08.010
44. El-Bizri, N., Guignabert, C., Wang, L., Cheng, A., Stankunas, K., Chang, C. P., et al. (2008). SM22α-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. Development 135, 2981-2991. doi: 10.1242/dev.017863
45. Fang, J. S., Dai, C., Kurjiaka, D. T., Burt, J. M., and Hirschi, K. K. (2013). Connexin45 regulates endothelial-induced mesenchymal cell differentiation toward a mural cell phenotype. Arterioscler. Thromb. Vasc. Biol. 33, 362-368. doi: 10.1161/ATVBAHA.112.255950
46. Feng, X. H., and Derynck, R. (2005). Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659-693. doi: 10.1146/annurev.cellbio.21.022404.142018
47. Fernandez-L, A., Sanz-Rodriguez, F., Zarrabeitia, R., Pérez-Molino, A., Hebbel, R. P., Nguyen, J., et al. (2005). Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc. Res. 68, 235-248. doi: 10.1016/j.cardiores.2005.06.009
48. Fernández-Klett, F., Offenhauser, N., Dirnagl, U., Priller, J., and Lindauer, U. (2010). Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc. Natl. Acad. Sci. U.S.A. 107, 22290-22295. doi: 10.1073/pnas.1011321108
49. Gaengel, K., Genové, G., Armulik, A., and Betsholtz, C. (2009). Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 630-638. doi: 10.1161/ATVBAHA.107.161521
50. Gaillard, S., Dupuis-Girod, S., Boutitie, F., Rivière, S., Morinière, S., Hatron, P. Y., et al. (2014). Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J. Thromb. Haemost. 12, 1494-1502. doi: 10.1111/jth.12654
51. Gallione, C. J., Repetto, G. M., Legius, E., Rustgi, A. K., Schelley, S. L., Tejpar, S., et al. (2004). A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363, 852-859. doi: 10.1016/S0140-6736(04)15732-2
52. Gallione, C. J., Richards, J. A., Letteboer, T. G., Rushlow, D., Prigoda, N. L., Leedom, T. P., et al. (2006). Smad4 mutations found in unselected HHT patients. J. Med. Genet. 43, 793-797. doi: 10.1136/jmg.2006.041517
53. Garrido-Martin, E. M., Nguyen, H. L., Cunningham, T. A., Choe, S. W., Jiang, Z., Arthur, H. M., et al. (2014). Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models-brief report. Arterioscler. Thromb. Vasc. Biol. 34, 2232-2236. doi: 10.1161/ATVBAHA.114.303984
54. Geisthoff, U. W., Seyfert, U. T., Kübler, M., Bieg, B., Plinkert, P. K., and König, J. (2014). Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb. Res. 134, 565-571. doi: 10.1016/j.thromres.2014.06.012
55. Gerhardt, H., and Betsholtz, C. (2003). Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314, 15-23. doi: 10.1007/s00441-003-0745-x
56. Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163-1177. doi: 10.1083/jcb.200302047
57. Gerhardt, H., Wolburg, H., and Redies, C. (2000). N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Dev. Dyn. 218, 472-479. doi: 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-
58. Geudens, I., and Gerhardt, H. (2011). Coordinating cell behaviour during blood vessel formation. Development 138, 4569-4583. doi: 10.1242/dev.062323
59. Girerd, B., Montani, D., Coulet, F., Sztrymf, B., Yaici, A., Jaïs, X., et al. (2010). Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am. J. Respir. Crit. Care Med. 181, 851-861. doi: 10.1164/rccm.200908-1284OC
60. Gore, B., Izikki, M., Mercier, O., Dewachter, L., Fadel, E., Humbert, M., et al. (2014). Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension. PLoS ONE 29:e100310. doi: 10.1371/journal.pone.0100310
61. Gossage, J. R., Chamberlain, S. M., Sridhar, S., and Kumar, A. (2009). An interim report of thalidomide for treatment of recurrent angioectasia related gastrointestinal bleeding. Hemat. Meet. Rep. 2009, 3.
62. Goumans, M. J., Valdimarsdottir, G., Itoh, S., Lebrin, F., Larsson, J., Mummery, C., et al. (2003). Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell 12, 817-828. doi: 10.1016/S1097-2765(03)00386-1
63. Goumans, M. J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., and ten Dijke, P. (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 21, 1743-1753. doi: 10.1093/emboj/21.7.1743
64. Govani, F. S., and Shovlin, C. L. (2010). Fine mapping of the hereditary haemorrhagic telangiectasia (HHT)3 locus on chromosome 5 excludes VE-Cadherin-2, Sprouty4 and other interval genes. J. Angiogenes. Res. 2:15. doi: 10.1186/2040-2384-2-15
65. Hall, C. N., Reynell, C., Gesslein, B., Hamilton, N. B., Mishra, A., Sutherland, B. A., et al. (2014). Capillary pericytes regulate cerebral blood flow in health and disease. Nature 508, 55-60. doi: 10.1038/nature13165
66. Hamilton, N. B., Attwell, D., and Hall, C. N. (2010). Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front. Neuroenergetics 2:5. doi: 10.3389/fnene.2010.00005
67. Han, C., Choe, S. W., Kim, Y. H., Acharya, A. P., Keselowsky, B. G., Sorg, B. S., et al. (2014). VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis 17, 823-830. doi: 10.1007/s10456-014-9436-3
68. Hellström, M., Phng, L. K., and Gerhardt, H. (2007). VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh. Migr. 1, 133-136. doi: 10.4161/cam.1.3.4978
69. Hirschi, K. K., Burt, J. M., Hirschi, K. D., and Dai, C. (2003). Gap junction communication mediates transforming growth factor-beta activation and endothelial-induced mural cell differentiation. Circ. Res. 93, 429-437. doi: 10.1161/01.RES.0000091259.84556.D5
70. Hong, K. H., Lee, Y. J., Lee, E., Park, S. O., Han, C., Beppu, H., et al. (2008). Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 118, 722-730. doi: 10.1161/CIRCULATIONAHA.107.736801
71. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., et al. (2010). Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350. doi: 10.1126/science.1177319
72. Itoh, F., Itoh, S., Adachi, T., Ichikawa, K., Matsumura, Y., Takagi, T., et al. (2012). Smad2/Smad3 in endothelium is indispensable for vascular stability via S1PR1 and N-cadherin expressions. Blood 119, 5320-5328. doi: 10.1182/blood-2011-12-395772
73. Itoh, F., Itoh, S., Carvalho, R. L., Adachi, T., Ema, M., Goumans, M. J., et al. (2009). Poor vessel formation in embryos from knock-in mice expressing ALK5 with L45 loop mutation defective in Smad activation. Lab. Invest. 89, 800-810. doi: 10.1038/labinvest.2009.37
74. Jakobsson, L., Franco, C. A., Bentley, K., Collins, R. T., Ponsioen, B., Aspalter, I. M., et al. (2010). Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 12, 943-953. doi: 10.1038/ncb2103
75. Jakobsson, L., and van Meeteren, L. A. (2013). Transforming growth factor β family members in regulation of vascular function: in the light of vascular conditional knockouts. Exp. Cell Res. 319, 1264-1270. doi: 10.1016/j.yexcr.2013.02.015
76. Johnson, D. W., Berg, J. N., Baldwin, M. A., Gallione, C. J., Marondel, I., Yoon, S. J., et al. (1996). Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 13, 189-195. doi: 10.1038/ng0696-189
77. Keller, A., Westenberger, A., Sobrido, M. J., García-Murias, M., Domingo, A., Sears, R. L., et al. (2013). Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat. Genet. 45, 1077-1082. doi: 10.1038/ng.2723
78. Kim, J. H., Peacock, M. R., George, S. C., and Hughes, C. C. (2012). BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II. Angiogenesis 15, 497-509. doi: 10.1007/s10456-012-9277-x
79. Krueger, M., and Bechmann, I. (2010). CNS pericytes: concepts, misconceptions, and a way out. Glia 58, 1-10. doi: 10.1002/glia.20898
80. Krüger, O., Plum, A., Kim, J. S., Winterhager, E., Maxeiner, S., Hallas, G., et al. (2000). Defective vascular development in connexin 45-deficient mice. Development 127, 4179-4193.
81. Kurstin, R. (2002). Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology 16, 21-24.
82. Larrivée, B., Prahst, C., Gordon, E., del Toro, R., Mathivet, T., Duarte, A., et al. (2012). ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev. Cell 22, 489-500. doi: 10.1016/j.devcel.2012.02.005
83. Larsson, J., Goumans, M. J., Sjöstrand, L. J., van Rooijen, M. A., Ward, D., and Levéen, P. (2001). Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J. 20, 1663-1673. doi: 10.1093/emboj/20.7.1663
84. Lebrin, F., Goumans, M. J., Jonker, L., Carvalho, R. L., Valdimarsdottir, G., Thorikay, M., et al. (2004). Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 23, 4018-4028. doi: 10.1038/sj.emboj.7600386
85. Lebrin, F., Srun, S., Raymond, K., Martin, S., van den Brink, S., Freitas, C., et al. (2010). Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med. 16, 420-428. doi: 10.1038/nm.2131
86. Lesca, G., Olivieri, C., Burnichon, N., Pagella, F., Carette, M. F., Gilbert-Dussardier, B., et al. (2007). Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet. Med. 9, 14-22. doi: 10.1097/GIM.0b013e31802d8373
87. Lesnik, G. T., Ross, D. A., Henderson, K. J., Joe, J. K., Leder, S. B., White, R. I., et al. (2007). Septectomy and septal dermoplasty for the treatment of severe transfusion-dependent epistaxis in patients with hereditary hemorrhagic telangiectasia and septal perforation. Am. J. Rhinol. 21, 312-315. doi: 10.2500/ajr.2007.21.3017
88. Letarte, M., McDonald, M. L., Li, C., Kathirkamathamby, K., Vera, S., Pece-Barbara, N., et al. (2005). Reduced endothelial secretion and plasma levels of transforming growth factor-beta1 in patients with hereditary hemorrhagic telangiectasia type 1. Cardiovasc. Res. 68, 155-164. doi: 10.1016/j.cardiores.2005.04.028
89. Letteboer, T. G., Mager, J. J., Snijder, R. J., Koeleman, B. P., Lindhout, D., Ploos van Amstel, J. K., et al. (2006). Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J. Med. Genet. 43, 371-377. doi: 10.1136/jmg.2005.035451
90. Li, D. Y., Sorensen, L. K., Brooke, B. S., Urness, L. D., Davis, E. C., Taylor, D. G., et al. (1999). Defective angiogenesis in mice lacking endoglin. Science 284, 1534-1537. doi: 10.1126/science.284.5419.1534
91. Li, F., Lan, Y., Wang, Y., Wang, J., Yang, G., Meng, F., et al. (2011). Endothelial Smad4 maintains cerebrovascular integrity by activating N-Cadherin through cooperation with notch. Dev. Cell. 20, 291-302. doi: 10.1016/j.devcel.2011.01.011
92. Liu, D., Wang, J., Kinzel, B., Müeller, M., Mao, X., Valdez, R., et al. (2007). Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood 110, 1502-1510. doi: 10.1182/blood-2006-11-058594
93. Lobov, I. B., Renard, R. A., Papadopoulos, N., Gale, N. W., Thurston, G., Yancopoulos, G. D., et al. (2007). Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl. Acad. Sci. U.S.A. 104, 3219-3224. doi: 10.1073/pnas.0611206104
94. Lopes, M., Goupille, O., Saint Cloment, C., Lallemand, Y., Cumano, A., and Robert, B. (2011). Msx genes define a population of mural cell precursors required for head blood vessel maturation. Development 138, 3055-3066. doi: 10.1242/dev.063214
95. Mahmoud, M., Allinson, K. R., Zhai, Z., Oakenfull, R., Ghandi, P., Adams, R. H., et al. (2010). Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ. Res. 106, 1425-1433. doi: 10.1161/CIRCRESAHA.109.211037
96. Massagué, J., and Gomis, R. R. (2006). The logic of TGFbeta signaling. FEBS Lett. 580, 2811-2820. doi: 10.1016/j.febslet.2006.04.033
97. Mathiisen, T. M., Lehre, K. P., Danbolt, N. C., and Ottersen, O. P. (2010). The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58, 1094-1103. doi: 10.1002/glia.20990
98. McAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., et al. (1994). Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8, 345-351. doi: 10.1038/ng1294-345
99. Melchert, M., and List, A. (2007). The thalidomide saga. Int. J. Biochem. Cell Biol. 39, 1489-1499. doi: 10.1016/j.biocel.2007.01.022
100. Moustakas, A., and Heldin, C. H. (2005). Non-Smad TGF-beta signals. J. Cell Sci. 118, 3573-3584. doi: 10.1242/jcs.02554
101. Moya, I. M., Umans, L., Maas, E., Pereira, P. N., Beets, K., Francis, A., et al. (2012). Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev. Cell 22, 501-514. doi: 10.1016/j.devcel.2012.01.007
102. Mu, D., Cambier, S., Fjellbirkeland, L., Baron, J. L., Munger, J. S., Kawakatsu, H., et al. (2002). The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 157, 493-507. doi: 10.1083/jcb.200109100
103. Nehls, V., and Drenckhahn, D. (1993). The versatility of microvascular pericytes: from mesenchyme to smooth muscle? Histochemistry 99, 1-12. doi: 10.1007/BF00268014
104. Nguyen, H. L., Lee, Y. J., Shin, J., Lee, E., Park, S. O., McCarty, J. H., et al. (2011). TGF-β signaling in endothelial cells, but not neuroepithelial cells, is essential for cerebral vascular development. Lab. Invest. 91, 1554-1563. doi: 10.1038/labinvest.2011.124
105. Nicolas, G., Pottier, C., Maltête, D., Coutant, S., Rovelet-Lecrux, A., Legallic, S., et al. (2013). Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology 80, 181-187. doi: 10.1212/WNL.0b013e31827ccf34
106. Oh, S. P., Seki, T., Goss, K. A., Imamura, T., Yi, Y., Donahoe, P. K., et al. (2000). Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 97, 2626-2631 doi: 10.1073/pnas.97.6.2626
107. Oshima, M., Oshima, H., and Taketo, M. M. (1996). TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 179, 297-302. doi: 10.1006/dbio.1996.0259
108. Owens, G. K. (1998). Molecular control of vascular smooth muscle cell differentiation. Acta Physiol. Scand. 164, 623-635. doi: 10.1111/j.1365-201X.1998.tb10706.x
109. Park, C., Lavine, K., Mishina, Y., Deng, C. X., Ornitz, D. M., and Choi, K. (2006). Bone morphogenetic protein receptor 1A signaling is dispensable for hematopoietic development but essential for vessel and atrioventricular endocardial cushion formation. Development 133, 3473-3484. doi: 10.1242/dev.02499
110. Park, S. O., Lee, Y. J., Seki, T., Hong, K. H., Fliess, N., Jiang, Z., et al. (2008). ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111, 633-642. doi: 10.1182/blood-2007-08-107359
111. Park, S. O., Wankhede, M., Lee, Y. J., Choi, E. J., Fliess, N., Choe, S. W., et al. (2009). Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 119, 3487-3496. doi: 10.1172/JCI39482
112. Penaloza, A., Vekemans, M. C., Lambert, C., and Hermans, C. (2011). Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Blood Coagul. Fibrinolysis. 22, 616-618. doi: 10.1097/MBC.0b013e32834a040c
113. Peppiatt, C. M., Howarth, C., Mobbs, P., and Attwell, D. (2006). Bidirectional control of CNS capillary diameter by pericytes. Nature 443, 700-704. doi: 10.1038/nature05193
114. Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887. doi: 10.1016/j.cell.2011.08.039
115. Ribatti, D., and Crivellato, E. (2012). "Sprouting angiogenesis," a reappraisal. Dev. Biol. 372, 157-165. doi: 10.1016/j.ydbio.2012.09.018
116. Ricard, N., Bidart, M., Mallet, C., Lesca, G., Giraud, S., Prudent, R., et al. (2010). Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations. Blood 116, 1604-1612. doi: 10.1182/blood-2010-03-276881
117. Ricard, N., Ciais, D., Levet, S., Subileau, M., Mallet, C., Zimmers, T. A., et al. (2012). BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood 119, 6162-6171. doi: 10.1182/blood-2012-01-407593
118. Riss, D., Burian, M., Wolf, A., Kranebitter, V., Kaider, A., and Arnoldner, C. (2014). Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck. doi: 10.1002/hed.23655. [Epub ahead of print].
119. Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., et al. (2002). Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16, 2684-2698. doi: 10.1101/gad.242002
120. Saba, H. I., Morelli, G. A., and Logrono, L. A. (1994). Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N. Engl. J. Med. 330, 1789-1790. doi: 10.1056/NEJM199406233302504
121. Sadick, H., Hage, J., Goessler, U., Bran, G., Riedel, F., Bugert, P., et al. (2008). Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF? Int. J. Mol. Med. 22, 575-580.
122. Sadick, H., Naim, R., Gössler, U., Hörmann, K., and Riedel, F. (2005a). Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int. J. Mol. Med. 15, 15-19.
123. Sadick, H., Riedel, F., Naim, R., Göessler, U., Hörmann, K., Hafner, M., et al. (2005b). Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90, 818-828.
124. Sadick, H., Riedel, F., Oulmi, J., Hörmann, K., and Bergler, W. F. (2003). [Argon plasma coagulation and topically applied estriol. Long-term results in the treatment of hereditary hemorrhagic telangiectasia of the nasal mucosa]. HNO 51, 118-124. doi: 10.1007/s00106-002-0666-0
125. Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., et al. (2013). Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat. Commun. 4, 2932. doi: 10.1038/ncomms3932
126. Sato, Y., and Rifkin, D. B. (1989). Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J. Cell Biol. 109, 309-315. doi: 10.1083/jcb.109.1.309
127. Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R. L., Zhao, Q., Pukac, L., et al. (2007). BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964-972. doi: 10.1242/jcs.002949
128. Seay, U., Sedding, D., Krick, S., Hecker, M., Seeger, W., and Eickelberg, O. (2005). Transforming growth factor-beta-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J. Pharmacol. Exp. Ther. 315, 1005-1012. doi: 10.1124/jpet.105.091249
129. Seki, T., Hong, K. H., and Oh, S. P. (2006). Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab. Invest. 86, 116-129. doi: 10.1038/labinvest.3700376
130. Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., et al. (2011). Latent TGF-β structure and activation. Nature 474, 343-349. doi: 10.1038/nature10152
131. Shortt, J., Hsu, A. K., and Johnstone, R. W. (2013). Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 32, 4191-4202. doi: 10.1038/onc.2012.599
132. Shovlin, C. L. (2010). Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 24, 203-219. doi: 10.1016/j.blre.2010.07.001
133. Sims, M. E. (1986). The pericyte-a review. Tissue Cell 18, 53-174. doi: 10.1016/0040-8166(86)90026-1
134. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571. doi: 10.1056/NEJM199911183412102
135. Speirs, A. L. (1962). Thalidomide and congenital abnormalities. Lancet 1, 303-305. doi: 10.1016/S0140-6736(62)91248-5
136. Sridurongrit, S., Larsson, J., Schwartz, R., Ruiz-Lozano, P., and Kaartinen, V. (2008). Signaling via the Tgf-β type I receptor Alk5 in heart development. Dev. Biol. 322, 208-218. doi: 10.1016/j.ydbio.2008.07.038
137. Srinivasan, S., Hanes, M. A., Dickens, T., Porteous, M. E., Oh, S. P., Hale, L. P., et al. (2003). A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum. Mol. Genet. 12, 473-482. doi: 10.1093/hmg/ddg050
138. Stapor, P. C., Sweat, R. S., Dashti, D. C., Betancourt, A. M., and Murfee, W. L. (2014). Pericyte dynamics during angiogenesis: new insights from new identities. J. Vasc. Res. 51, 163-174. doi: 10.1159/000362276
139. Stark, K., Eckart, A., Haidari, S., Tirniceriu, A., Lorenz, M., von Brühl, M. L., et al. (2013). Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and 'instruct' them with pattern-recognition and motility programs. Nat. Immunol. 14, 41-51. doi: 10.1038/ni.2477
140. Suchting, S., Freitas, C., le Noble, F., Benedito, R., Bréant, C., Duarte, A., et al. (2007). The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. U.S.A. 104, 3225-3230. doi: 10.1073/pnas.0611177104
141. Tammela, T., Zarkada, G., Wallgard, E., Murtomäki, A., Suchting, S., Wirzenius, M., et al. (2008). Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656-660. doi: 10.1038/nature07083
142. Therapontos, C., Erskine, L., Gardner, E. R., Figg, W. D., and Vargesson, N. (2009). Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci. U.S.A. 106, 8573-8578. doi: 10.1073/pnas.0901505106
143. Torsney, E., Charlton, R., Diamond, A. G., Burn, J., Soames, J. V., and Arthur, H. M. (2003). Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 107, 1653-1657. doi: 10.1161/01.CIR.0000058170.92267.00
144. Tual-Chalot, S., Mahmoud, M., Allinson, K. R., Redgrave, R. E., Zhai, Z., Oh, S. P., et al. (2014). Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression. PLoS ONE 9:e98646. doi: 10.1371/journal.pone.0098646
145. Umans, L., Cox, L., Tjwa, M., Bito, V., Vermeire, L., Laperre, K., et al. (2007). Inactivation of Smad5 in endothelial cells and smooth muscle cells demonstrates that Smad5 is required for cardiac homeostasis. Am. J. Pathol. 170, 1460-1472. doi: 10.2353/ajpath.2007.060839
146. Umans, L., Vermeire, L., Francis, A., Chang, H., Huylebroeck, D., and Zwijsen, A. (2003). Generation of a floxed allele of Smad5 for cre-mediated conditional knockout in the mouse. Genesis 37, 5-11. doi: 10.1002/gene.10219
147. Urness, L. D., Sorensen, L. K., and Li, D. Y. (2000). Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet. 26, 328-331. doi: 10.1038/81634
148. Van Cutsem, E., Rutgeerts, P., Geboes, K., Van Gompel, F., and Vantrappen, G. (1988). Estrogen-progesterone treatment of Osler-Weber-Rendu disease. J. Clin. Gastroenterol. 10, 676-679. doi: 10.1097/00004836-198812000-00022
149. van Cutsem, E., Rutgeerts, P., and Vantrappen, G. (1990). Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 335, 953-955. doi: 10.1016/0140-6736(90)91010-8
150. Van Geest, R. J., Klaassen, I., Vogels, I. M., Van Noorden, C. J., and Schlingemann, R. O. (2010). Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy? Invest. Ophthalmol. Vis. Sci. 51, 1857-1865. doi: 10.1167/iovs.09-4181
151. van Gent, M. W., Post, M. C., Snijder, R. J., Westermann, C. J., Plokker, H. W., and Mager, J. J. (2010). Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 138, 833-839. doi: 10.1378/chest.09-1849
152. van Laake, L. W., van den Driesche, S., Post, S., Feijen, A., Jansen, M. A., Driessens, M. H., et al. (2006). Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 114, 2288-2297. doi: 10.1161/CIRCULATIONAHA.106.639161
153. Wacker, A., and Gerhardt, H. (2011). Endothelial development taking shape. Curr. Opin. Cell Biol. 23, 676-685. doi: 10.1016/j.ceb.2011.10.002
154. Walker, E. J., Su, H., Shen, F., Degos, V., Amend, G., Jun, K., et al. (2012). Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke 43, 1925-1930. doi: 10.1161/STROKEAHA.111.647982
155. Winkler, E. A., Bell, R. D., and Zlokovic, B. V. (2011). Lack of Smad or Notch leads to a fatal game of brain pericyte hopscotch. Dev. Cell 20, 279-280. doi: 10.1016/j.devcel.2011.03.002
156. Winkler, E. A., Sagare, A. P., and Zlokovic, B. V. (2014). The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol. 24, 371-386. doi: 10.1111/bpa.12152
157. Wooderchak-Donahue, W. L., McDonald, J., O'Fallon, B., Upton, P. D., Li, W., Roman, B. L., et al. (2013). BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am. J. Hum. Genet. 93, 530-537. doi: 10.1016/j.ajhg.2013.07.004
158. Xu, B., Wu, Y. Q., Huey, M., Arthur, H. M., Marchuk, D. A., and Hashimoto, T. (2004). Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain. J. Cereb. Blood Flow Metab. 24, 237-244. doi: 10.1097/01.WCB.0000107730.66603.51
159. Yang, X., Castilla, L. H., Xu, X., Li, C., Gotay, J., Weinstein, M., et al. (1999). Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 126, 1571-1580.
160. Yaniv, E., Preis, M., Hadar, T., Shvero, J., and Haddad, M. (2009). Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 119, 284-288. doi: 10.1002/lary.20065
161. Young, K., Conley, B., Romero, D., Tweedie, E., O'Neill, C., Pinz, I., et al. (2012). BMP9 regulates endoglin-dependent chemokine responses in endothelial cells. Blood 120, 4263-4273. doi: 10.1182/blood-2012-07-440784
162. Yu, P. B., Beppu, H., Kawai, N., Li, E., and Bloch, K. D. (2005). Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J. Biol. Chem. 280, 24443-24450. doi: 10.1074/jbc.M502825200
163. Yu, P. B., Deng, D. Y., Beppu, H., Hong, C. C., Lai, C., Hoyng, S. A., et al. (2008). Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J. Biol. Chem. 283, 3877-3888. doi: 10.1074/jbc.M706797200
164. Zhu, J., Motejlek, K., Wang, D., Zang, K., Schmidt, A., and Reichardt, L. F. (2002). beta8 integrins are required for vascular morphogenesis in mouse embryos. Development 129, 2891-2903.
165. Zhu, Y. X., Kortuem, K. M., and Stewart, A. K. (2013). Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma 54, 683-687. doi: 10.3109/10428194.2012.728597